All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
How can we identify early the best responders to ide-cel?
Featured
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How can we identify early the best responders to idecabtagene vicleucel (ide-cel)?
How can we identify early the best responders to ide-cel?
In this interview, the results of the KarMMa phase II clinical trial are discussed, as presented at the 64th ASH Annual Meeting and Exposition. Paiva examines measurable residual disease (MRD) compared with serological response following ide-cel and the ideal timepoint for assessing depth of response. Paiva concludes by describing the relationship between early undetectable MRD following ide-cel infusion and progression-free survival in patients with relapsed/refractory multiple myeloma.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox